DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies

Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anemia

Intervention: No intervention (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


The purpose of this study is to assess the presence of anti erythropoietin antibodies (anti EPO Ab) in participants responding to any erythropoietin receptor agonist (ERA) therapy to treat or prevent anemia without loss of effectiveness to see if they will develop pure red cell aplasia or loss of effectiveness to recombinant erythropoietin and to measure the duration of effectiveness of ERA therapy.

Clinical Details

Official title: An Observational Study of Subjects Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Number of Participants With Presence of Anti-Erythropoietin Antibodies (anti-EPO Ab)

Duration of Effectiveness of Erythropoietin Receptor Agonist Therapy

Secondary outcome:

Concentration of Plasma Anti Erythropoietin Antibody

Factors That Forecast Progression to Loss of Effectiveness

Factors That Forecast Progression to Suspected Pure Red Cell Aplasia

Factors That Forecast Progression to Confirmed Pure Red Cell Aplasia

Number of Participants With Adverse Events

Detailed description: This is an observational (study in which the investigators/physicians observe the participant's data and measure their outcomes), international, multicenter (study conducted at multiple sites), cohort (group of individuals with similar characteristics) study. The study consists of prestudy phase, observational phase (2 years), and follow-up phase (1 year). Approximately 50 participants who already receiving ERA therapy for anemia will be observed in this study. In the observational phase, participants' erythropoietin antibody status (positive or negative), clinical progress, treatment for anemia or prevention of anemia, and outcome will be monitored. During this study, enrolled participants will continue to receive standard-of-care treatment for their disease from their individual investigators as before enrollment to this study. Safety evaluations will include assessment of adverse events which will be monitored throughout the study. The total duration of the study will be 3 years.


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Receiving any ERA therapy for any cause of anemia and having responded to the ERA

therapy for at least 3 months

- Positive or borderline serum for antibodies to erythropoietin identified by serum


- Maintained a stable hemoglobin within a 3-month period that has not decreased more

than 2 g/dL in any 1-month period and with no increase in red blood cell transfusion requirement

- An ERA maintenance dose that has not increased more than 50 percentages from initial

effective dose

- If blood count information is available, must have a count of reticulocytes (immature

red blood cells) greater than or equal to 30 million/L Exclusion Criteria:

- Stem cell or bone marrow transplantation

- Treatment with medication that decreases the ability of the immune system to function

normally, within the last 3 months

- Participants who have shown a loss of effectiveness to ERA therapy, defined as

participants who initially responded to treatment for anemia [a rise in hemoglobin which lasted for a minimum of 3 months] followed by an unexplained decrease in hemoglobin (greater than or equal to 2 g/dL) within a 1-month period

Locations and Contacts

Additional Information

Starting date: December 2005
Last updated: August 29, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017